Company intelligence / Profile preview

Jadi Cell

Elk City, Idaho, United States

Ownership: Private
Development stage: Other

Overview

JadiCell mesenchymal stem cell therapy has demonstrated 100% survival in COVID-19 ARDS patients under age 85 in a double-blind Phase 1/2 trial, showing anti-inflammatory and regenerative effects superior to other stem cell sources; it is in Phase 3 for ARDS and has Right to Try and preclinical programs for various neuroinflammatory and neurodegenerative diseases

Therapeutic areas: Infectious DiseasesPulmonologyPsychiatryNeurology
Modalities: Cell therapyMesenchymal stem cellAdult stem cell therapy
Industry: Biotech

Partnerships

Therapeutic Solutions International (exclusive licensee for clinical use in brain and lung indications)Allogen Biologics (TSOI subsidiary; manufacturing partner for JadiCell products)

Beyond the preview

Go deeper on Jadi Cell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jadi Cell.

Explore the full profile